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Edited by Gerrit van MeerAbstract Foam cell formation due to excessive accumulation of
cholesterol by macrophages is a pathological hallmark of athero-
sclerosis. Macrophages cannot limit the uptake of cholesterol
and therefore depend on cholesterol eﬄux pathways for prevent-
ing their transformation into foam cells. Several ABC-transport-
ers, including ABCA1 and ABCG1, facilitate the eﬄux of
cholesterol from macrophages. These transporters, however, also
aﬀect membrane lipid asymmetry which may have important
implications for cellular endocytotic pathways. We propose that
in addition to the generally accepted role of these ABC-trans-
porters in the prevention of foam cell formation by induction
of cholesterol eﬄux from macrophages, they also inﬂuence the
macrophage endocytotic uptake.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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asymmetry1. Introduction
Atherosclerotic cardiovascular disease is the major cause of
morbidity and mortality worldwide [1]. A pathological hall-
mark of atherosclerosis is the excessive accumulation of cho-
lesterol by macrophages leading to their transformation into
foam cells [2]. Macrophages play an important role in the ini-
tiation of the early atherosclerotic lesions. In addition, during
the further progression of the lesion, macrophages also con-
tribute to the formation of the necrotic core and may aﬀect
the stability of the atherosclerotic lesion. Especially in the ini-
tiation of atherosclerosis, cholesterol homeostasis in macro-
phages is of prime importance, as dysregulation of the
balance of cholesterol inﬂux and cholesterol eﬄux will lead
to excessive accumulation of cholesterol in the macrophage
and their transformation into foam cells. This minireview high-
lights important aspects of macrophage cholesterol homeosta-
sis.*Corresponding author. Fax: +31 71 5276032.
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Cholesterol may entermacrophages via several diﬀerent path-
ways. Macrophages express high levels of scavenger receptors,
which bind and internalize oxidatively modiﬁed lipoproteins.
Furthermore, macrophages also contain several other types of
binding sites that are involved in the accumulation of unmodi-
ﬁed lipoproteins and lipoprotein remnants, including the LDL
receptor (LDLr), LDL receptor-related protein (LRP), VLDL
receptor (VLDLr), and proteoglycans (see Fig. 1).
An important receptor implicated in the accumulation of
oxidatively modiﬁed lipoproteins is scavenger receptor A
(SR-A). SR-A is highly expressed in macrophage-derived foam
cells in atherosclerotic plaques [3–5]. It binds many polyan-
ionic molecules, but the aﬃnity of SR-A for modiﬁed lipopro-
teins varies. The uptake of acetylated LDL (AcLDL) and
oxidized LDL (OxLDL) by SR-A deﬁcient macrophages was
30% and 70% of that in wildtype macrophages, respectively
[6,7], while AcLDL degradation in SR-A deﬁcient macro-
phages was 17% of control [8]. Total body SR-A deﬁciency re-
sulted in 50% and 20% reduction in atherosclerotic lesion
size in apoE knockout (apoE/) and LDL receptor knockout
mice (LDLr/), respectively [6,9]. Using the technique of
bone marrow transplantation, Linton et al. [10] generated
C57Bl/6 mice and LDLr/ mice that were selectively deﬁcient
for SR-A in macrophages. In both mouse models a 60% reduc-
tion in lesion area was observed in absence of macrophage SR-
A, indicating an important pro-atherogenic role of SR-A
expression by macrophages. Macrophage SR-A overexpres-
sion in LDLr/ mice and apoE/ mice, however, did not sig-
niﬁcantly aﬀect atherosclerotic lesion development [11,12].
SR-A belongs to a growing list of scavenger receptor family
members (for review [13]). In addition to SR-A, also CD36 was
shown to bind and internalize minimally modiﬁed forms of
LDL [14]. Peritoneal macrophages of CD36 deﬁcient mice
exhibit a 60–80% decrease in OxLDL binding [15]. While
SR-A appeared to be more important for AcLDL and fully
oxidized LDL binding and degradation, CD36 was more ac-
tive towards mildly oxidized LDL [16]. In macrophages from
SR-A/CD36 double knockout mice the degradation of AcLDL
and OxLDL was inhibited for 75–90% while the cholesteryl es-
ters from modiﬁed lipoproteins failed to accumulate and no
foam cell forming was possible. These data establish that
SR-A and CD36 are responsible for the preponderance of
modiﬁed LDL uptake in macrophages and that other scavengerblished by Elsevier B.V. All rights reserved.
Fig. 1. Macrophage cholesterol accumulation. Cholesterol may enter
macrophages via several diﬀerent pathways and induce the transfor-
mation of macrophages into foam cells, the ﬁrst step in atherosclerotic
lesion development [2]. Scavenger receptors, including scavenger
receptor A (SR-A), scavenger receptor BI (SR-BI), and CD36 mediate
the uptake of modiﬁed lipoproteins by macrophages. Native lipopro-
teins are taken up via the LDL receptor (LDLr), the VLDL receptor
(VLDLr), and LDL receptor related protein 1 (LRP1). Furthermore,
cholesterol may enter macrophages via ﬂuid-phase macropinocytosis.
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showed recently that the lipid accumulation in macrophages
induced by native LDL from apoE/ mice is also blocked
for 80% by the absence of SR-A and CD36. ApoE/ mice
reconstituted with CD36-deﬁcient bone marrow displayed a
88% reduction in lesion area after 12 weeks Western-type diet
feeding [18], establishing the essential role of macrophage
CD36 in lesion formation. On the other hand, Moore et al.
recently reported that deletion of SR-A or CD36 does not
ameliorate atherosclerosis in apoE/ mice [19]. The reason
for this absence of an eﬀect is presently unclear. It might either
indicate that modiﬁed lipoproteins are less important in lesion
formation as currently thought or that additional (patho-
logical) stimulants, i.e. bacterial pathogens, are needed to
evoke the crucial role of these scavenger receptors.
Scavenger receptor BI (SR-BI), an HDL receptor which
mediates the selective uptake of cholesterol esters from HDL
by the liver [20,21] is also expressed by lipid-laden macrophages
in human and murine atherosclerotic lesions [22–24]. It binds
native and modiﬁed lipoproteins, anionic phospholipids, and
apoptotic cells [25]. In addition to its role in the selective uptake
of HDL cholesteryl esters, SR-BI stimulates the bi-directional
ﬂux of free cholesterol between cells and HDL and the rate of
cholesterol eﬄux from various cell types correlates with the
expression of SR-BI [26–28]. Bone marrow transplantation
studies have shown that SR-BI on macrophages reduces the
development of advanced atherosclerotic lesions in LDLr/
[29,30] and apoE/ mice [31]. In contrast, the development
of small fatty streak lesions in LDLr/ mice is facilitated by
macrophage SR-BI [30]. It thus appears that, depending on
the stage of lesion development, SR-BI in macrophages is either
proatherogenic or antiatherogenic, indicating a dual role for
SR-BI in the pathogenesis of atherosclerosis. This unique dual
role is probably a direct eﬀect of the ﬁnding that SR-BI is a
multi-functional, multi-ligand receptor that facilitates the bind-
ing of a wide array of native and modiﬁed lipoproteins and
mediates the bi-directional ﬂux of cholesterol between HDL
and cells. Its function in the binding of atherogenic lipopro-
teins, like native VLDL and oxidized LDL is expected to induce
foam cell formation, while eﬄux of intracellular cholesterol to
HDL will prevent foam cell formation and thus atherosclerotic
lesion development.In addition to SR-BI, also members of the LDL receptor
family, including the LDL receptor, LRP1, and the VLDL
receptor have been implicated in macrophage foam cell forma-
tion. The LDL receptor is a major pathway for the uptake of
VLDL by macrophages [32,33]. However, for long the role of
the macrophage LDL receptor in foam cell formation and ath-
erosclerotic lesion development was thought to be limited, as it
is rapidly downregulated upon cellular cholesterol accumula-
tion [34]. However, by performing bone marrow transplanta-
tion studies, we [35] and others [36] have provided in vivo
evidence that the macrophage LDL receptor facilitates diet-in-
duced atherosclerosis. In addition, to the LDL receptor, also
the VLDL receptor is abundantly expressed by macrophage-
derived foam cells in atherosclerotic lesions [37–39]. In con-
trast to the LDL receptor, the expression of the VLDL
receptor is not responsive to cholesterol loading [40]. Further-
more, reconstitution of macrophage VLDL receptor expres-
sion in VLDL receptor knockout mice largely increased
atherosclerotic lesion development, indicating that the macro-
phage VLDLr is a pro-atherogenic factor [41]. LRP1 is a
multi-ligand and multi-functional receptor involved in a vari-
ety of physiological processes, including the uptake of apoE-
containing lipoproteins [42]. Macrophage-speciﬁc LRP1
knockout mice, however, display a reduced susceptibility to
atherosclerotic lesion development, indicating that macro-
phage LRP1 is protective and that the pro-atherogenic func-
tion of LRP1 in the accumulation of lipids by macrophages
is limited in vivo [43].
The majority of the processes described above for macro-
phage cholesterol accumulation involve rapid receptor-medi-
ated coated-pit endocytosis. In addition, modiﬁed LDL
is taken up by macrophages in part by the slower process
of macropinocytosis [44]. At high concentrations (0.5–2 mg/
ml), native LDL can induce macrophage foam cell formation
in PMA-activated [45,46] and M-CSF-diﬀerentiated [47]
human monocyte-derived macrophages by ﬂuid-phase macr-
opinocytosis. Macropinocytosis, ﬁrst described by Lewis in
1931 [48], is the actin-dependent formation of large vesicles,
allowing the internalization of large quantities of ﬂuid-phase
solute (for review [49]). It is a major endocytotic pathway in
epithelial cells, ﬁbroblasts, neutrophils, and macrophages
that occurs constitutively, but is highly increased by growth
factors, such as epidermal growth factor (EGF) [50], macro-
phage colony stimulating factor (M-CSF) [51,52], and phorbol
esters [53,54]. Macropinosomes are dynamic structures formed
by the closure of lamellipodia at ruﬄing membranes and
range in size from 0.2 to 5 m in diameter [49]. In unstimulated
macrophages, membrane ruﬄes are relatively small and sel-
dom form macropinosomes [54]. After stimulation by PMA
or M-CSF, the ruﬄes transform into longer and broader
lamellipodia that regularly form macropinosomes by resealing
with the cell surface, enclosing extracellular medium
[52,54]. Macropinosomes start as early endosomes derived
from the plasma and rapidly mature into late endosomes
and ﬁnally merge into a stable, resident lysomal compartment
[55].
Although most studies on macropinocytosis are performed
on cells in vitro, in vivo spleen, lymph nodes, and liver are
organs active in ﬂuid-phase endocytosis [56]. Furthermore,
ﬂuid-phase uptake in Kupﬀer cells, resident macrophages of
the liver, takes place via macropinocytosis in vivo [57]. Thus,
it is also plausible that this constitutive uptake of ﬂuid-phase
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wall.3. ABC-transporters: key molecules for macrophage cholesterol
eﬄux
Macrophages are incapable of limiting the uptake of lipids
via the wide variety of uptake mechanisms described above
and therefore, largely depend on cholesterol eﬄux pathways
to maintain cellular lipid homeostasis. A key transporter in-
volved in the eﬄux of cholesterol and phospholipids from mac-
rophages is ATP-binding cassette transporter A1 (ABCA1)
[58] (see Fig. 2). ABCA1 is a 2261-amino acid, 240-kDa pro-
tein belonging to a large family of conserved transmembrane
proteins that use ATP as an energy source to transport a wide
variety of substrates across cellular membranes [59]. It is a full
transporter, consisting of two 6-helix transmembrane domains
that serve as a pathway for the translocation of substrates
across membranes and two nucleotide-binding domains that
bind ATP and provide the energy for transport. ABCA1 medi-
ates the transport of cholesterol and phospholipids to lipid-free
apolipoproteins such as apoAI [60]. Macrophage ABCA1
expression is highly upregulated by oxysterol-dependent trans-
activation of the ABCA1 promoter by the liver X receptor
(LXR) [61,62]. Furthermore, ABCA1 is highly expressed in
atherosclerotic lesions, where it co-localizes with cholesterol-
loaded macrophages [63]. Bone marrow transplantation exper-
iments showed that disruption of ABCA1 in macrophages
results in a marked increase in atherosclerotic lesion develop-
ment [64,65]. Thus, ABCA1-dependent cholesterol eﬄux is a
crucial factor in the prevention of excessive cholesterol accu-
mulation in macrophages of the arterial wall and their trans-
formation into foam cells. By transplantation of ABCA1
overexpressing bone marrow into LDLr/ mice, we have re-
cently provided the ﬁrst evidence that ABCA1 expression by
macrophages plays a critical role in the protection against
the progression of atherosclerosis [66].
In addition to ABCA1, macrophages also express ABCG1,
which is induced during cholesterol uptake in macrophages
[67,68] and is activated via LXR [69,70]. ABCG1 is a half
transporter with a single 6-helix transmembrane domain and
a single nucleotide domain that needs to form a homodimerFig. 2. Macrophage cholesterol eﬄux. Macrophages cannot limit the
uptake of cholesterol and therefore depend on cholesterol eﬄux
pathways for the prevention of excessive cholesterol accumulation and
atherosclerotic lesion development [2]. ABCA1 facilitates the eﬄux of
cholesterol from macrophages to lipid-poor apoAI, while ABCG1 and
SR-BI mediate the eﬄux of cholesterol to mature HDL. In addition,
other transporters of the ABC-transporter superfamily might mediate
cholesterol eﬄux from macrophages.or a heterodimer with another ABC-transporter to be func-
tional. In contrast to ABCA1, ABCG1 facilitates cellular cho-
lesterol and phospholipid eﬄux from macrophages to mature
HDL, but not to lipid-free apolipoproteins [71–73]. ABCA1-
mediated lipid eﬄux, however, transforms lipid-free apoAI
into an eﬃcient substrate for ABCG1-dependent eﬄux, sug-
gesting that ABCA1 and ABCG1 might synergize to mediate
cholesterol eﬄux to apoAI [75]. Macrophages isolated from
ABCG1 knockout mice display a reduction in cholesterol
eﬄux capacity upon treatment with LXR activators [72,75,76].
Furthermore, targeted disruption of ABCG1 in mice results
in massive lipid accumulation in macrophages within lungs
and multiple other tissues upon high-fat, high-cholesterol diet
feeding, while overexpression of ABCG1 protects tissues from
dietary induced lipid accumulation [72,75]. ABCG1 thus plays
a critical role in preventing cellular lipid accumulation. Since
ABCG1 is expressed by macrophage-derived foam cells in
the human atherosclerotic plaque [77], it is anticipated that
macrophage ABCG1 will also play an important role in
atherosclerotic lesion development. To assess the role of
macrophage ABCG1 in atherosclerosis, we recently generated
LDLr/ mice that are selectively deﬁcient in macrophage
ABCG1 by using bone marrow transfer [78]. After 12 weeks
of feeding a high-cholesterol diet containing 0.25% cholesterol
and 15% fat lungs of the LDLr/ mice, reconstituted with
ABCG1 knockout bone marrow showed a striking accumula-
tion of lipids in macrophages localized to the subpleural
region. Furthermore, both after 6 weeks and 12 weeks of
high-cholesterol diet feeding macrophage ABCG1 deﬁciency
resulted in a moderate 33–36% increase in lesion formation.
Under the same conditions, macrophage ABCA1 deﬁciency,
however, did lead to a 2-fold increase in lesion development
in LDLr/ mice after both 6 (unpublished results) and 12
weeks on the high-cholesterol diet [64], establishing that at
both time points the potential eﬀect of ABCG1 deﬁciency on
atherosclerotic lesion formation is certainly less prominent as
compared to ABCA1.
Both ABCA1 and ABCG1 belong to a large family of evo-
lutionary conserved transmembrane proteins that use the
energy of ATP hydrolysis to translocate a wide variety of
substrates across cellular membranes. To date, 51 members
of the family of ABC-transporters have been identiﬁed, which,
based on structural similarities, have been subdivided into
seven families, designated ABC A-G [59,79,80]. A vast major-
ity of these ABC-transporter genes are expressed by macro-
phages and show cholesterol inﬂux or eﬄux dependent gene
regulation [67,81]. It is therefore conceivable that a signiﬁcant
portion of the cholesterol-responsive ABC-transporters may
be involved in macrophage lipid homeostasis and play pivotal
roles in foam cell formation and atherogenesis.
The closest relatives of ABCA1 that are expressed by macro-
phages and display cholesterol-responsive regulation are
ABCA2 [82], ABCA6 [83], ABCA7 [84–87], ABCA9 [88],
and ABCA10 [89]. ABCA7 has recently been shown to mediate
phospholipid eﬄux to apoAI [86,87,90], while also a role in
cholesterol eﬄux has been indicated [87]. Like ABCA1,
ABCA7 is sensitive to LXR activation [81], and the expression
is upregulated by cholesterol loading and downregulated upon
cholesterol eﬄux to HDL [84]. However, disruption of ABCA7
expression in macrophages did not aﬀect phospholipid or cho-
lesterol eﬄux to apoAI [86]. Moreover, in ABCA1-knockout
macrophages, there was no detectable apoAI-stimulated
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ABCA7.
Also members of the ABCB-subfamily of ABC-transporters
have been implicated in macrophage lipid homeostasis.
ABCB1, a ubiquitous transporter which confers multidrug
resistance [91] is upregulated upon diﬀerentiation from mono-
cytes to macrophages and is highly responsive to activation by
LXR agonists [81]. Furthermore, increased ABCB1 mRNA
was found in atherosclerotic specimens, suggesting a role for
ABCB1 in atherosclerotic lesion development in vivo [92].
The exact role of ABCB1 in macrophage lipid homeostasis,
however is still unclear. Some studies suggest that ABCB1
mediates the esteriﬁcation of plasma membrane cholesterol
[93,94], while more recently using a speciﬁc inhibitor of
ABCB1 evidence was provided that the esteriﬁcation of choles-
terol is not correlated with ABCB1 activity [95]. Recently, Le
Goﬀ et al. also showed that cholesterol eﬄux is increased in
ABCB1 stably transfected drug-selected LLC-MDR1 cells,
but not in the ABCB1-inducible HeLaMDR-Tet and 77.1
MDR-Tet cells [96]. Another ABC-transporter that is ex-
pressed by macrophages is ABCB4, which plays an important
role in the secretion of phospholipids into the bile [97]. Inter-
estingly, in contrast to ABCA1, expression of ABCB4 is down-
regulated by cholesterol loading and upregulated by
cholesterol eﬄux [67]. In addition to ABCG1 [70,67], also
ABCG4 [98] of the ABCG subfamily of ABC-transporters
shows cholesterol-responsive regulation in macrophages and
promotes cholesterol eﬄux from cells to HDL [74]. ABCG4
has been suggested to be the heterodimeric partner for ABCG1
[99]. However, no eﬀect of macrophage ABCG4 deﬁciency was
observed on cholesterol eﬄux from macrophages [77]. Finally,
other LXR-regulated ABC-transporters expressed by macro-
phages include ABCB9, ABCB11, ABCC2, ABCC5, ABCD1,
ABCD1, ABCD4, and ABCG2 [81].
Thus although some members of the ABC-transporter
superfamily might be more attractive candidates than others,
currently still little is known about the exact function of most
of the cholesterol-responsive ABC-transporters in macro-
phages in vivo and their potential relevance for the process
of foam cell formation and atherosclerotic lesion development.Fig. 3. Regulation of membrane asymmetry by transbilayer movement
of phospholipids. Lipids in plasma membranes of eukaryotic cells are
asymmetrically distributed between the inner and outer membrane
leaﬂet. Phosphatidylcholine (PC) and sphingomyelin (SM) are primar-
ily located on the external leaﬂet, while phosphatidylserine (PS),
phosphatidylethanolamine (PE), and phosphatidylinositol (PI) are
concentrated in the internal leaﬂet. The generation and maintenance of
membrane lipid asymmetry is mediated by the interplay of diﬀerent
transporters, including the aminophospholipid translocase or ‘‘ﬂip-
pase’’, which transports PS and PE from the outer leaﬂet to the inner
leaﬂet and ‘‘ﬂoppases’’ that transport lipids in the opposite direction
from inside to outside. Several members of the ABC-transporter
superfamily, including ABCA1, ABCG1, and ABCB4 are recognized
as ‘‘ﬂoppases’’. ‘‘Scramblases’’, which are activated by e.g. cell injury
or programmed cell death, lead to loss of the membrane asymmetry.
Adapted from Graham, T.R. [132].4. ABC-transporters in regulation of plasma membrane lipid
asymmetry; implications for macrophage foam cell formation
Lipids in plasma membranes of eukaryotic cells are asym-
metrically distributed between the inner and outer membrane
leaﬂet [100]. The choline-containing phospholipids, phosphati-
dylcholine (PC) and sphingomyelin (SM) are primarily located
on the external leaﬂet, while the amine-containing glycero-
phospholipids, phosphatidylserine (PS) and phosphatidyletha-
nolamine (PE) are concentrated in the internal leaﬂet. In
addition, the minor phospholipids phosphatidic acid (PA),
phosphatidylinositol (PI), phosphatidylinositol-4-monophos-
phate (PIP), and phosphatidylinositol-4,5-biphosphate (PIP2)
are enriched at the cytoplasmic leaﬂet. The generation and
maintenance of membrane lipid asymmetry is mediated by
the interplay of diﬀerent transporters (for review [101,102]).
Two classes of ATP-dependent transporters of lipids can be
distinguished: (1) the aminophospholipid translocase or ‘‘ﬂip-
pase’’, which transports PS and PE from the outer leaﬂet to
the inner leaﬂet and (2) ‘‘ﬂoppases’’ that transport lipids inthe opposite direction from inside to outside. In circumstances
of cell activation, cell injury, or programmed cell death (apop-
tosis) extensive remodeling of membrane phospholipids asym-
metry occurs resulting in rapid egress of PS and PE to the cell
surface. This is mediated by non-selective ‘‘scramblases’’ [103]
(see Fig. 3).
Interestingly, several members of the ABC-transporter
superfamily are recognized as ‘‘ﬂoppases’’. ABCC1, or multi-
drug resistance-associated protein MRP1, has been implicated
in the active transport of PC and SM to the outer leaﬂet of the
membrane. Inhibition of ABCC1 results in decreased amounts
of BSA-extractable NBD-labelled PC and SM analogs in
erythrocyte membranes [104]. Furthermore, erythrocytes from
ABCC1 knockout mice show enhanced accumulation of NBD-
labelled PS analog [105]. Interestingly, inhibition of ABCC1
for prolonged periods of time also results in signiﬁcantly smal-
ler amounts of PC and SM present in the outer leaﬂet of eryth-
rocyte membranes, suggesting that ABCC1 might also be
involved in the maintenance of the outward orientation of
endogenous choline-containing phospholipids [104]. ABCB1,
a ubiquitous transporter which confers multidrug resistance,
actively transports hydrophobic molecules from the inner to
the outer leaﬂet of the plasma membrane [91]. Recently, it
was demonstrated that it functions as a broad-speciﬁcity ‘‘ﬂop-
pase’’ for NBD-labled phospholipid analogs, including PC,
PE, and SM [106,107] and simple glycosphingolipids [108].
ABCB4 functions as a selective ‘‘ﬂoppase’’ for PC [106]. Mice
deﬁcient for ABCB4 develop severe damage to both the hepa-
tocytes and the bile ducts of the liver as a result of impaired
phospholipid secretion into the bile [97]. Furthermore, using
ﬁbroblasts from transgenic mice expressing human ABCB4 it
was conﬁrmed that ABCB4 promotes the transfer of PC from
the inner to the outer leaﬂet of the plasma membrane [109].
Erythrocytes from mice with a homozygous disruption of
ABCB1 or ABCB4 displayed reduced PC cell surface translo-
cation, supporting a role for these transporters in natural PC
translocation [110]. Although both ABCB4 and ABCB1 can
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absence of ABCB4 in transporting PC into the bile of ABCB4
knockout mice [97].
Several studies have shown that the levels of PS in the outer
leaﬂet of cells are directly related to the expression level of
ABCA1, providing evidence that ABCA1 functions as a PS
‘‘ﬂoppase’’ and pumps PS from the inner leaﬂet to the outer
leaﬂet of the cellular membrane [111–113]. Indeed, compared
to ABCA1 wild-type mice, erythrocytes from ABCA1 knock-
out mice expose reduced amounts of PS after stimulation with
a Ca2+-ionophore [111]. In addition, ABCA1 mediates the ef-
ﬂux of PC [114]. Recently, Kobayashi et al. provided evidence
that in addition to PC, ABCA1 also transports SM, but that it
has a preference for PC [115].
ABCG1, which facilitates cholesterol eﬄux to mature HDL,
also transports PC [67,74] and SM [115]. In contrast to
ABCA1, ABCG1 preferentially mediates the secretion of SM
over PC [115]. Interestingly, disruption of the ABCG1 gene
in mice not only results in the tissue accumulation of choles-
terol, but also of phospholipids, while overexpression of
ABCG1 results in decreased tissue phospholipid levels. [73].
Mutations in ABCG5 and ABCG8 cause sitosterolemia which
is characterized by elevated plasma levels of phytosterols due
to increased intestinal absorption and impaired biliary secre-
tion of sterols [116]. In contrast to ABC-transporters with
outward directed ‘‘ﬂoppase’’ activity, the retina-speciﬁc
ABC-transporter ABCA4 is an inward directed ‘‘ﬂippase’’ that
transports retinal PE derivates [117].
In the presence of an acceptor molecule, the ‘ﬂopping’ of lip-
ids from the inner to the outer leaﬂet of the membrane can re-
sult in a net ﬂux of lipids, such as phospholipids and
cholesterol, across the lipid bilayer and into the luminal space.
This process of cholesterol eﬄux will prevent the transforma-
tion of macrophages into foam cells. On the other hand, alter-
ations in the lipid balance across the bilayer of the plasma
membrane plays a critical role in membrane budding and
endocytosis [118,119]. This is a combined eﬀect of the increase
in the number of lipids in one leaﬂet as well as the molecular
shape of the phospholipids. The headgroup and the lipid back-
bone of PC and PS have similar cross-sectional areas and are
thus cylindrical, while PE with a small headgroup is cone-
shaped [120]. Transbilayer transport of lipids thus leads to a
diﬀerence in the surface area between both membrane mono-
layers and induces bending of the membrane. In agreement,
incorporation of additional amounts of PC and SM in the
outer leaﬂet of the plasma membrane results in reduced endo-
cytosis [121]. Furthermore, transport of PS from the external
to the internal leaﬂet of the plasma membrane by the ‘‘ﬂip-
pase’’ aminophospholipid translocase enhances endocytosis
[122,123], while disruption of this transport results in defective
endocytosis [124].
Interestingly, absence of ABCA1 in Tangier ﬁbroblasts has
also been associated with enhanced endocytosis, probably as
a result of reduction of the surface area diﬀerence between
the two membrane leaﬂets due to the transport of PS to the out-
er leaﬂet [125]. Conversely, Alder-Baerens et al. demonstrated
that overexpression of ABCA1-GFP results in reduced recep-
tor-mediated endocytosis of ﬂuorescent transferrin and reduced
ﬂuid-phase endocytosis [126]. Increased endocytosis in absence
of ABCA1 can be normalized through the addition of synthetic
PS to the outer leaﬂet [125]. Thus, ABC-transporters with
‘‘ﬂoppase’’ activity can reduce receptor-mediated and ﬂuid-phase endocytosis by alteration the asymmetry of the plasma
membrane lipid bilayer. Both receptor-mediated endocytosis
and ﬂuid-phase macropinocytosis are important processes in-
volved in the induction of macrophage foam cell formation.
Thus, in addition to the generally accepted role of the ABC-
transporters ABCA1 and ABCG1 in prevention of foam cell
formation by induction of cholesterol eﬄux frommacrophages,
these transporters are also expected to inhibit the uptake of lip-
ids by macrophages. In agreement, it was shown that upregula-
tion of macrophage ABCA1 and ABCG1 by LXR activation,
not only reduces macrophage foam cell formation by inducing
macrophage cholesterol eﬄux but also by inhibiting ﬂuid-phase
macropinocytosis of LDL [127]. In addition, recently we have
demonstrated that speciﬁc disruption of ABCB4 in macro-
phages promoted macrophage foam cell formation and athero-
sclerotic lesion development [128]. The increased foam cell
formation in absence of ABCB4 was not the eﬀect of macro-
phage ABCB4-deﬁciency on cholesterol and PC eﬄux, but
rather of increased accumulation of modiﬁed LDL [129].5. Perspectives
Current therapeutic strategies to prevent atherosclerosis are
primarily based on the use of statins, inhibitors of the novo
cholesterol synthesis that decrease serum LDL cholesterol lev-
els thereby inhibiting the uptake of native and oxidatively
modiﬁed LDL by macrophages in the arterial wall [130,131].
Despite the proven eﬀectiveness of statins and their widespread
use, the incidence of cardiovascular disease still remains high,
indicating that there is an important need for new alternative
therapies. With the discovery of the role of ABCA1 in macro-
phage cholesterol eﬄux, we have entered a new era in which
the superfamily of evolutionary conserved ABC-transporters
is linked to the pathogenesis of atherosclerosis. Although since
the discovery of ABCA1 already several additional ABC-
transporters have been implicated in macrophage cholesterol
eﬄux, the quantitative role of these transporters in macro-
phage cholesterol homeostasis is still unknown. For instance,
SR-BI and ABCG1 contribute for only 20% and 22%, respec-
tively, to the transport of cholesterol from macrophages to
HDL indicating that still unidentiﬁed gene products are
responsible for the cholesterol eﬄux to HDL. The identiﬁca-
tion of additional relevant transporters for cholesterol eﬄux
to HDL forms a short term scientiﬁc challenge. On a longer
term the modulation of ABC-transporters might lead to new
therapeutic approaches which will lead to regression of (ad-
vanced) atherosclerotic lesions with potential beneﬁcial eﬀects
for treatment of cardiovascular disease.Acknowledgments: This work was supported by The Netherlands
Heart Foundation (Grants 2001T041 and 2003B134) and The Nether-
lands Organization for Scientiﬁc Research (Grants 902-23-149 and
912-02-063).References
[1] Hennekens, C.H. (1998) Increasing burden of cardiovascular
disease: current knowledge and future directions for research on
risk factors. Circulation 97, 1095–1102.
[2] Ross, R. (1999) Atherosclerosis – an inﬂammatory disease. New
Engl. J. Med. 340, 115–126.
M. Pennings et al. / FEBS Letters 580 (2006) 5588–5596 5593[3] Naito, M., Suzuki, H., Mori, T., Matsumoto, A., Kodama, T.
and Takahashi, K. (1992) Coexpression of type I and type II
human macrophage scavenger receptors in macrophages of
various organs and foam cells in atherosclerotic lesions. Am. J.
Pathol. 141, 591–599.
[4] Matsumoto, A., Naito, M., Itakura, H., Ikemoto, S., Asaoka,
H., Hayakawa, I., Kanamori, H., Aburatani, H., Takaku, F. and
Suzuki, H., et al. (1990) Human macrophage scavenger recep-
tors: primary structure, expression, and localization in athero-
sclerotic lesions. Proc. Natl. Acad. Sci. USA 87, 9133–9137.
[5] Hiltunen, T.P., Luoma, J.S., Nikkari, T. and Yla-Herttuala, S.
(1998) Expression of LDL receptor, VLDL receptor, LDL
receptor-related protein, and scavenger receptor in rabbit
atherosclerotic lesions: marked induction of scavenger receptor
and VLDL receptor expression during lesion development.
Circulation 97, 1079–1086.
[6] Suzuki, H., Kurihara, Y., Takeya, M., Kamada, N., Kataoka,
M., Jishage, K., Ueda, O., Sakaguchi, H., Higashi, T., Suzuki,
T., Takashima, Y., Kawabe, Y., Cynshi, O., Wada, Y., Honda,
M., Kurihara, H., Aburatani, H., Doi, T., Matsumoto, A.,
Azuma, S., Noda, T., Toyoda, Y., Itakura, H., Yazaki, Y. and
Kodama, T., et al. (1997) A role for macrophage scavenger
receptors in atherosclerosis and susceptibility to infection.
Nature 386, 292–296.
[7] Lougheed, M., Lum, C.M., Ling, W., Suzuki, H., Kodama, T.
and Steinbrecher, U. (1997) High aﬃnity saturable uptake of
oxidized low density lipoprotein by macrophages from mice
lacking the scavenger receptor class A type I/II. J. Biol. Chem.
272, 12938–12944.
[8] Van Berkel, T.J., Van Velzen, A., Kruijt, J.K., Suzuki, H. and
Kodama, T. (1998) Uptake and catabolism of modiﬁed LDL in
scavenger-receptor class A type I/II knock-out mice. Biochem. J.
331, 29–35.
[9] Sakaguchi, H., Takeya, M., Suzuki, H., Hakamata, H., Kod-
ama, T., Horiuchi, S., Gordon, S., van der Laan, L.J., Kraal, G.,
Ishibashi, S., Kitamura, N. and Takahashi, K. (1998) Role of
macrophage scavenger receptors in diet-induced atherosclerosis
in mice. Lab. Invest. 78, 423–434.
[10] Babaev, V.R., Gleaves, L.A., Carter, K.J., Suzuki, H., Kodama,
T., Fazio, S. and Linton, M.F. (2000) Reduced atherosclerotic
lesions in mice deﬁcient for total or macrophage-speciﬁc
expression of scavenger receptor-A. Arterioscler. Thromb. Vasc.
Biol. 20, 2593–2599.
[11] Herijgers, N., de Winther, M.P., Van Eck, M., Havekes, L.M.,
Hofker, M.H., Hoogerbrugge, P.M. and Van Berkel, T.J. (2000)
Eﬀect of human scavenger receptor class A overexpression in
bone marrow-derived cells on lipoprotein metabolism and
atherosclerosis in low density lipoprotein receptor knockout
mice. J. Lipid Res. 41, 1402–1409.
[12] Van Eck, M., De Winther, M.P., Herijgers, N., Havekes, L.M.,
Hofker, M.H., Groot, P.H. and Van Berkel, T.J. (2000) Eﬀect of
human scavenger receptor class A overexpression in bone
marrow-derived cells on cholesterol levels and atherosclerosis
in ApoE-deﬁcient mice. Arterioscler. Thromb. Vasc. Biol. 20,
2600–2606.
[13] Van Berkel, T.J., Out, R., Hoekstra, M., Kuiper, J., Biessen, E.
and Van Eck, M. (2005) Scavenger receptors: friend or foe in
atherosclerosis? Curr. Opin. Lipidol. 16, 525–535.
[14] Endemann, G., Stanton, L.W., Madden, K.S., Bryant, C.M.,
White, R.T. and Protter, A.A. (1993) CD36 is a receptor for
oxidized low density lipoprotein. J. Biol. Chem. 268, 11811–
11816.
[15] Febbraio, M., Abumrad, N.A., Hajjar, D.P., Sharma, K.,
Cheng, W., Pearce, S.F. and Silverstein, R.L. (1999) A null
mutation in murine CD36 reveals an important role in fatty acid
and lipoprotein metabolism. J. Biol. Chem. 274, 19055–19062.
[16] Kunjathoor, V.V., Febbraio, M., Podrez, E.A., Moore, K.J.,
Andersson, L., Koehn, S., Rhee, J.S., Silverstein, R., Hoﬀ, H.F.
and Freeman, M.W. (2002) Scavenger receptors class A-I/II and
CD36 are the principal receptors responsible for the uptake of
modiﬁed low density lipoprotein leading to lipid loading in
macrophages. J. Biol. Chem. 277, 49982–49988.
[17] Zhao, Z., de Beer, M.C., Cai, L., Asmis, R., de Beer, F.C., de
Villiers, W.J. and van der Westhuyzen, D.R. (2005) Low-density
lipoprotein from apolipoprotein E-deﬁcient mice induces macro-phage lipid accumulation in a CD36 and scavenger receptor class
A-dependent manner. Arterioscler. Thromb. Vasc. Biol. 25, 168–
173.
[18] Febbraio, M., Guy, E. and Silverstein, R.L. (2004) Stem cell
transplantation reveals that absence of macrophage CD36 is
protective against atherosclerosis. Arterioscler. Thromb. Vasc.
Biol. 24, 2333–2338.
[19] Moore, K.J., Kunjathoor, V.V., Koehn, S.L., Manning, J.J.,
Tseng, A.A., Silver, J.M., McKee, M. and Freeman, M.W.
(2005) Loss of receptor-mediated lipid uptake via scavenger
receptor A or CD36 pathways does not ameliorate atheroscle-
rosis in hyperlipidemic mice. J. Clin. Invest. 115, 2192–2201.
[20] Acton, S., Rigotti, A., Landschulz, K.T., Xu, S., Hobbs, H.H.
and Krieger, M. (1996) Identiﬁcation of scavenger receptor
SR-BI as a high density lipoprotein receptor. Science 271, 518–
520.
[21] Out, R., Hoekstra, M., Spijkers, J.A., Kruijt, J.K., Van Eck, M.,
Bos, I.S., Twisk, J. and Van Berkel, T.J. (2004) Scavenger
receptor class B type I is solely responsible for the selective
uptake of cholesteryl esters from HDL by the liver and the
adrenals in mice. J. Lipid Res. 45, 2088–2095.
[22] Ji, Y., Jian, B., Wang, N., Sun, Y., Moya, M.L., Phillips, M.C.,
Rothblat, G.H., Swaney, J.B. and Tall, A.R. (1997) Scavenger
receptor BI promotes high density lipoprotein-mediated cellular
cholesterol eﬄux. J. Biol. Chem. 272, 20982–20985.
[23] Chinetti, G., Gbaguidi, F.G., Griglio, S., Mallat, Z., Antonucci,
M., Poulain, P., Chapman, J., Fruchart, J.C., Tedgui, A., Najib-
Fruchart, J. and Staels, B. (2000) CLA-1/SR-BI is expressed in
atherosclerotic lesion macrophages and regulated by activators
of peroxisome proliferator-activated receptors. Circulation 101,
2411–2417.
[24] Hirano, K., Yamashita, S., Nakagawa, Y., Ohya, T., Matsuura,
F., Tsukamoto, K., Okamoto, Y., Matsuyama, A., Matsumoto,
K., Miyagawa, J. and Matsuzawa, Y. (1999) Expression of
human scavenger receptor class B type I in cultured human
monocyte-derived macrophages and atherosclerotic lesions. Circ.
Res. 85, 108–116.
[25] Rigotti, A., Acton, S.L. and Krieger, M. (1995) The class B
scavenger receptors SR-BI and CD36 are receptors for anionic
phospholipids. J. Biol. Chem. 270, 16221–16224.
[26] de la Llera-Moya, M., Rothblat, G.H., Connelly, M.A., Kellner-
Weibel, G., Sakr, S.W., Phillips, M.C. and Williams, D.L. (1999)
Scavenger receptor BI (SR-BI) mediates free cholesterol ﬂux
independently of HDL tethering to the cell surface. J. Lipid Res.
40, 575–580.
[27] Yancey, P.G., de la Llera-Moya, M., Swarnakar, S., Monzo, P.,
Klein, S.M., Connelly, M.A., Johnson, W.J., Williams, D.L. and
Rothblat, G.H. (2000) High density lipoprotein phospholipid
composition is a major determinant of the bi-directional ﬂux and
net movement of cellular free cholesterol mediated by scavenger
receptor BI. J. Biol. Chem. 275, 36596–36604.
[28] Gu, X., Kozarsky, K. and Krieger, M. (2000) Scavenger receptor
class B, type I-mediated [3H]cholesterol eﬄux to high and low
density lipoproteins is dependent on lipoprotein binding to the
receptor. J. Biol. Chem. 275, 29993–30001.
[29] Covey, S.D., Krieger, M., Wang, W., Penman, M. and Trigatti,
B.L. (2003) Scavenger receptor class B type I-mediated protec-
tion against atherosclerosis in LDL receptor-negative mice
involves its expression in bone marrow-derived cells. Arterios-
cler. Thromb. Vasc. Biol. 23, 1589–1594.
[30] Van Eck, M., Bos, I.S., Hildebrand, R.B., Van Rij, B.T. and Van
Berkel, T.J. (2004) Dual role for scavenger receptor class B, type
I on bone marrow-derived cells in atherosclerotic lesion devel-
opment. Am. J. Pathol. 165, 785–794.
[31] Zhang, W., Yancey, P.G., Su, Y.R., Babaev, V.R., Zhang, Y.,
Fazio, S. and Linton, M.F. (2003) Inactivation of macrophage
scavenger receptor class B type I promotes atherosclerotic lesion
development in apolipoprotein E-deﬁcient mice. Circulation 108,
2258–2263.
[32] Koo, C., Wernette-Hammond, M.E., Garcia, Z., Malloy, M.J.,
Uauy, R., East, C., Bilheimer, D.W., Mahley, R.W. and
Innerarity, T.L. (1988) Uptake of cholesterol-rich remnant
lipoproteins by human monocyte-derived macrophages is med-
iated by low density lipoprotein receptors. J. Clin. Invest. 81,
1332–2340.
5594 M. Pennings et al. / FEBS Letters 580 (2006) 5588–5596[33] Perrey, S., Ishibashi, S., Kitamine, T., Osuga, J., Yagyu, H.,
Chen, Z., Shionoiri, F., Iizuka, Y., Yahagi, N., Tamura, Y.,
Ohashi, K., Harada, K., Gotoda, T. and Yamada, N. (2001)
The LDL receptor is the major pathway for beta-VLDL
uptake by mouse peritoneal macrophages. Atherosclerosis 154,
51–60.
[34] Brown, M.S. and Goldstein, J.L. (1975) Regulation of the
activity of the low density lipoprotein receptor in human
ﬁbroblasts. Cell 6, 307–316.
[35] Herijgers, N., Van Eck, M., Korporaal, S.J., Hoogerbrugge,
P.M. and Van Berkel, T.J. (2000) Relative importance of the
LDL receptor and scavenger receptor class B in the beta-VLDL-
induced uptake and accumulation of cholesteryl esters by
peritoneal macrophages. J. Lipid Res. 41, 1163–1171.
[36] Linton, M.F., Babaev, V.R., Gleaves, L.A. and Fazio, S. (1999)
A direct role for the macrophage low density lipoprotein
receptor in atherosclerotic lesion formation. J. Biol. Chem.
274, 19204–19210.
[37] Multhaupt, H.A., Gafvels, M.E., Kariko, K., Jin, H., Arenas-
Elliot, C., Goldman, B.I., Strauss 3rd, J.F., Angelin, B., Warhol,
M.J. and McCrae, K.R. (1996) Expression of very low density
lipoprotein receptor in the vascular wall. Analysis of human
tissues by in situ hybridization and immunohistochemistry. Am.
J. Pathol. 148, 1985–1997.
[38] Nakazato, K., Ishibashi, T., Shindo, J., Shiomi, M. and
Maruyama, Y. (1996) Expression of very low density lipoprotein
receptor mRNA in rabbit atherosclerotic lesions. Am. J. Pathol.
149, 1831–1838.
[39] Argraves, K.M., Kozarsky, K.F., Fallon, J.T., Harpel, P.C. and
Strickland, D.K. (1997) The atherogenic lipoprotein Lp(a) is
internalized and degraded in a process mediated by the VLDL
receptor. J. Clin. Invest. 100, 2170–2181.
[40] Sakai, J., Hoshino, A., Takahashi, S., Miura, Y., Ishii, H.,
Suzuki, H., Kawarabayasi, Y. and Yamamoto, T. (1994)
Structure, chromosome location, and expression of the human
very low density lipoprotein receptor gene. J. Biol. Chem. 269,
2173–2182.
[41] Van Eck, M., Oost, J., Goudriaan, J.R., Hoekstra, M., Hilde-
brand, R.B., Bos, I.S., Willems Van Dijk, K. and Van Berkel,
T.J. (2005) Role of the macrophage very-low-density lipoprotein
receptor in atherosclerotic lesion development. Atherosclerosis
183, 230–237.
[42] Lillis, A.P., Mikhailenko, I. and Strickland, D.K. (2005) Beyond
endocytosis: LRP function in cell migration, proliferation and
vascular permeability. J. Thromb. Haemost. 3, 1884–1893.
[43] Hu, L., Boesten, L., Huisman, M., Meidnets, E., Havekes, L.,
Van Vlijmen, B. and Tamsma, J. (2005) Macrophage low-density
lipoprotein receptor-related protein deﬁciency enhances athero-
sclerosis. J. Vasc. Res. 42 (Suppl. 2), 55.
[44] Jones, N.L. and Willingham, M.C. (1999) Modiﬁed LDLs are
internalized by macrophages in part via macropinocytosis. Anat.
Rec. 255, 57–68.
[45] Kruth, H.S., Huang, W., Ishii, I. and Zhang, W.Y. (2002)
Macrophage foam cell formation with native low density
lipoprotein. J. Biol. Chem. 277, 34573–34580.
[46] Kruth, H.S., Jones, N.L., Huang, W., Zhao, B., Ishii, I., Chang,
J., Combs, C.A., Malide, D. and Zhang, W.Y. (2005) Macro-
pinocytosis is the endocytic pathway that mediates macrophage
foam cell formation with native low density lipoprotein. J. Biol.
Chem. 280, 2352–2360.
[47] Zhao, B., Li, Y., Buono, C., Waldo, S.W., Jones, N.L., Mori, M.
and Kruth, H.S. (2006) Constitutive receptor-independent low
density lipoprotein uptake and cholesterol accumulation by
macrophages diﬀerentiated from human monocytes with mac-
rophage-colony-stimulating factor (M-CSF). J. Biol. Chem. 281,
15757–15762.
[48] Lewis, W.H. (1931) Pinocytosis. Johns Hopkins Hosp. Bull. 49,
17–27.
[49] Swanson, J.A. and Watts, C. (1995) Macropinocytosis. Trends
Cell Biol. 5, 424–428.
[50] West, M.A., Bretscher, M.S. and Watts, C. (1989) Distinct
endocytotic pathways in epidermal growth factor-stimulated
human carcinoma A431 cells. J. Cell. Biol. 109, 2731–2739.
[51] Racoosin, E.L. and Swanson, J.A. (1992) M-CSF-induced
macropinocytosis increases solute endocytosis but not receptor-mediated endocytosis in mouse macrophages. J. Cell Sci. 102,
867–880.
[52] Racoosin, E.L. and Swanson, J.A. (1989) Macrophage colony-
stimulating factor (rM-CSF) stimulates pinocytosis in bone
marrow-derived macrophages. J. Exp. Med. 170, 1635–1648.
[53] Phaire-Washington, L., Wang, E. and Silverstein, S.C. (1980)
Phorbol myristate acetate stimulates pinocytosis and membrane
spreading in mouse peritoneal macrophages. Cell Biol. 86, 634–
640.
[54] Swanson, J.A. (1989) Phorbol esters stimulate macropinocytosis
and solute ﬂow through macrophages. J. Cell Sci. 94, 135–142.
[55] Racoosin, E.L. and Swanson, J.A. (1993) Macropinosome
maturation and fusion with tubular lysosomes in macrophages.
J. Cell Biol. 121, 1011–1020.
[56] Munniksma, J., Noteborn, M., Kooistra, T., Stienstra, S.,
Bouma, J.M., Gruber, M., Brouwer, A., Praaning-van Dalen,
D. and Knook, D.L. (1980) Fluid endocytosis by rat liver and
spleen. Experiments with 125I-labelled poly(vinylpyrrolidone)
in vivo. Biochem. J. 192, 613–621.
[57] Kjeken, R., Mousavi, S.A., Brech, A., Gjoen, T. and Berg, T.
(2001) Fluid phase endocytosis of [125I]iodixanol in rat liver
parenchymal, endothelial and Kupﬀer cells. Cell Tissue Res. 304,
221–230.
[58] Van Eck, M., Pennings, M., Hoekstra, M., Out, R. and Van
Berkel, T.J. (2005) Scavenger receptor BI and ATP-binding
cassette transporter A1 in reverse cholesterol transport and
atherosclerosis. Curr. Opin. Lipidol. 16, 307–315.
[59] Higgins, C.F. (1992) ABC transporters: from microorganisms to
man. Annu. Rev. Cell Biol. 8, 67–113.
[60] Rye, K.A. and Barter, P.J. (2004) Formation and metabolism of
prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler.
Thromb. Vasc. Biol. 24, 421–428.
[61] Costet, P., Luo, Y., Wang, N. and Tall, A.R. (2000) Sterol-
dependent transactivation of the ABC1 promoter by the liver X
receptor/retinoid X receptor. J. Biol. Chem. 275, 28240–28245.
[62] Schwartz, K., Lawn, R.M. and Wade, D.P. (2000) ABC1 gene
expression and ApoA-I-mediated cholesterol eﬄux are regulated
by LXR. Biochem. Biophys. Res. Commun. 274, 794–802.
[63] Lawn, R.M., Wade, D.P., Couse, T.L. and Wilcox, J.N. (2001)
Localization of human ATP-binding cassette transporter 1
(ABC1) in normal and atherosclerotic tissues. Arterioscler.
Thromb. Vasc. Biol. 21, 378–385.
[64] Van Eck, M., Bos, I.S., Kaminski, W.E., Orso, E., Rothe, G.,
Twisk, J., Bottcher, A., Van Amersfoort, E.S., Christiansen-
Weber, T.A., Fung-Leung, W.P., Van Berkel, T.J. and Schmitz,
G. (2002) Leukocyte ABCA1 controls susceptibility to athero-
sclerosis and macrophage recruitment into tissues. Proc. Natl.
Acad. Sci. USA 99, 6298–6303.
[65] Aiello, R.J., Brees, D., Bourassa, P.A., Royer, L., Lindsey, S.,
Coskran, T., Haghpassand, M. and Francone, O.L. (2002)
Increased atherosclerosis in hyperlipidemic mice with inactiva-
tion of ABCA1 in macrophages. Arterioscler. Thromb. Vasc.
Biol. 22, 630–637.
[66] Van Eck, M., Singaraja, R.R., Ye, D., Hildebrand, R.B., James,
E.R., Hayden, M.R. and Van Berkel, T.J. (2006) Macrophage
ATP-binding cassette transporter A1 overexpression inhibits
atherosclerotic lesion progression in low-density lipoprotein
receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 26,
929–934.
[67] Klucken, J., Buchler, C., Orso, E., Kaminski, W.E., Porsch-
Ozcurumez, M., Liebisch, G., Kapinsky, M., Diederich, W.,
Drobnik, W., Dean, M., Allikmets, R. and Schmitz, G. (2000)
ABCG1 (ABC8), the human homolog of the Drosophila white
gene, is a regulator of macrophage cholesterol and phospholipid
transport. Proc. Natl. Acad. Sci. USA 97, 817–822.
[68] Hoekstra, M., Kruijt, J.K., Van Eck, M. and Van Berkel, T.J.
(2003) Speciﬁc gene expression of ATP-binding cassette trans-
porters and nuclear hormone receptors in rat liver parenchymal,
endothelial, and Kupﬀer cells. J. Biol. Chem. 278, 25448–25453.
[69] Venkateswaran, A., Laﬃtte, B.A., Joseph, S.B., Mak, P.A.,
Wilpitz, D.C., Edwards, P.A. and Tontonoz, P. (2000) Control
of cellular cholesterol eﬄux by the nuclear oxysterol receptor
LXR alpha. Proc. Natl. Acad. Sci. USA 97, 12097–12102.
[70] Venkateswaran, A., Repa, J.J., Lobaccaro, J.M., Bronson, A.,
Mangelsdorf, D.J. and Edwards, P.A. (2000) Human white/
M. Pennings et al. / FEBS Letters 580 (2006) 5588–5596 5595murine ABC8 mRNA levels are highly induced in lipid-loaded
macrophages. A transcriptional role for speciﬁc oxysterols. J.
Biol. Chem. 275, 14700–14707.
[71] Jessup, W., Gelissen, I.C., Gaus, K. and Kritharides, L. (2006)
Roles of ATP binding cassette transporters A1 and G1,
scavenger receptor BI and membrane lipid domains in choles-
terol export from macrophages. Curr. Opin. Lipidol. 17, 247–
257.
[72] Kennedy, M.A., Barrera, G.C., Nakamura, K., Baldan, A.,
Tarr, P., Fishbein, M.C., Frank, J., Francone, O.L. and
Edwards, P.A. (2005) ABCG1 has a critical role in mediating
cholesterol eﬄux to HDL and preventing cellular lipid accumu-
lation. Cell Metab. 1, 121–131.
[73] Wang, N., Lan, D., Chen, W., Matsuura, F. and Tall, A.R.
(2004) ATP-binding cassette transporters G1 and G4 mediate
cellular cholesterol eﬄux to high-density lipoproteins. Proc.
Natl. Acad. Sci. USA 101, 9774–9779.
[74] Gelissen, I.C., Harris, M., Rye, K.A., Quinn, C., Brown, A.J.,
Kockx, M., Cartland, S., Packianathan, M., Kritharides, L. and
Jessup, W. (2006) ABCA1 and ABCG1 synergize to mediate
cholesterol export to apoA-I. Arterioscler. Thromb. Vasc. Biol.
26, 534–540.
[75] Baldan, A., Tarr, P., Lee, R. and Edwards, P.A. (2006) ATP-
binding cassette transporter G1 and lipid homeostasis. Curr.
Opin. Lipidol. 17, 227–232.
[76] Wang, N., Ranalletta, M., Matsuura, F., Peng, F. and Tall, A.R.
(2006) LXR-induced redistribution of ABCG1 to plasma mem-
brane in macrophages enhances cholesterol mass eﬄux to HDL.
Arterioscler. Thromb. Vasc. Biol. 26, 1310–1316.
[77] Lorkowski, S., Kratz, M., Wenner, C., Schmidt, R., Weitkamp,
B., Fobker, M., Reinhardt, J., Rauterberg, J., Galinski, E.A. and
Cullen, P. (2001) Expression of the ATP-binding cassette
transporter gene ABCG1 (ABC8) in Tangier disease. Biochem.
Biophys. Res. Commun. 283, 821–830.
[78] Out, R., Hoekstra, M., Hildebrand, R.B., Kruit, J.K., Meurs, I.,
Li, Z., Kuipers, F., Van Berkel, Th.J.C. and Van Eck, M. (2006)
Macrophage ABCG1 deletion disrupts lipid homeostasis in
alveolar macrophages and moderately inﬂuences atherosclerotic
lesion development in LDL receptor-deﬁcient mice. Arterioscler.
Thromb. Vasc. Biol. 20 (July), (Epub ahead of print).
[79] Dean, M. and Allikmets, R. (1995) Evolution of ATP-bind-
ing cassette transporter genes. Curr. Opin. Genet. Dev. 5, 779–
785.
[80] Dean, M., Rzhetsky, A. and Allikmets, R. (2001) The human
ATP-binding cassette (ABC) transporter superfamily. Genome
Res. 11, 1156–1166.
[81] Langmann, T., Mauerer, R. and Schmitz, G. (2006) Human
ATP-binding cassette transporter TaqMan low-density array:
analysis of macrophage diﬀerentiation and foam cell formation.
Clin. Chem. 52, 310–313.
[82] Kaminski, W.E., Piehler, A., Pullmann, K., Porsch-Ozcurumez,
M., Duong, C., Bared, G.M., Buchler, C. and Schmitz, G. (2001)
Complete coding sequence, promoter region, and genomic
structure of the human ABCA2 gene and evidence for sterol-
dependent regulation in macrophages. Biochem. Biophys. Res.
Commun. 281, 249–258.
[83] Kaminski, W.E., Wenzel, J.J., Piehler, A., Langmann, T. and
Schmitz, G. (2001) ABCA6, a novel a subclass ABC transporter.
Biochem. Biophys. Res. Commun. 285, 1295–1301.
[84] Kaminski, W.E., Orso, E., Diederich, W., Klucken, J., Drobnik,
W. and Schmitz, G. (2000) Identiﬁcation of a novel human
sterol-sensitive ATP-binding cassette transporter (ABCA7).
Biochem. Biophys. Res. Commun. 273, 532–538.
[85] Broccardo, C., Osorio, J., Luciani, M.F., Schriml, L.M., Prades,
C., Shulenin, S., Arnould, I., Naudin, L., Lafargue, C., Rosier,
M., Jordan, B., Mattei, M.G., Dean, M., Deneﬂe, P. and
Chimini, G. (2001) Comparative analysis of the promoter
structure and genomic organization of the human and mouse
ABCA7 gene encoding a novel ABCA transporter. Cytogenet.
Cell Genet. 92, 264–270.
[86] Wang, N., Lan, D., Gerbod-Giannone, M., Linsel-Nitschke, P.,
Jehle, A.W., Chen, W., Martinez, L.O. and Tall, A.R. (2003)
ATP-binding cassette transporter A7 (ABCA7) binds apolipo-
protein A-I and mediates cellular phospholipid but not choles-
terol eﬄux. J. Biol. Chem. 278, 42906–42912.[87] Abe-Dohmae, S., Ikeda, Y., Matsuo, M., Hayashi, M., Okuhira,
K., Ueda, K. and Yokoyama, S. (2004) Human ABCA7
supports apolipoprotein-mediated release of cellular cholesterol
and phospholipid to generate high density lipoprotein. J. Biol.
Chem. 279, 604–611.
[88] Piehler, A., Kaminski, W.E., Wenzel, J.J., Langmann, T. and
Schmitz, G. (2002) Molecular structure of a novel cholesterol-
responsive A subclass ABC transporter, ABCA9. Biochem.
Biophys. Res. Commun. 295, 408–416.
[89] Wenzel, J.J., Kaminski, W.E., Piehler, A., Heimerl, S., Lang-
mann, T. and Schmitz, G. (2003) ABCA10, a novel cholesterol-
regulated ABCA6-like ABC transporter. Biochem. Biophys. Res.
Commun. 306, 1089–1098.
[90] Linsel-Nitschke, P., Jehle, A.W., Shan, J., Cao, G., Bacic, D.,
Lan, D., Wang, N. and Tall, A.R. (2005) Potential role of
ABCA7 in cellular lipid eﬄux to apoA-I. J. Lipid Res. 46, 86–92.
[91] Higgins, C.F. and Gottesman, M.M. (1992) Is the multidrug
transporter a ﬂippase? Trends Biochem. Sci. 17, 18–21.
[92] Batetta, B., Mulas, M.F., Petruzzo, P., Putzolu, M., Bonatesta,
R.R., Sanna, F., Cappai, A., Brotzu, G. and Dessi, S. (2001)
Opposite pattern of MDR1 and caveolin-1 gene expression in
human atherosclerotic lesions and proliferating human smooth
muscle cells. Cell Mol. Life Sci. 58, 1113–1120.
[93] Debry, P., Nash, E.A., Neklason, D.W. and Metherall, J.E.
(1997) Role of multidrug resistance P-glycoproteins in choles-
terolesteriﬁcation. J. Biol. Chem. 272, 1026–1031.
[94] Luker, G.D., Nilsson, K.R., Covey, D.F. and Piwnica-Worms,
D. (1999) Multidrug resistance (MDR1) P-glycoprotein en-
hances esteriﬁcation of plasma membrane cholesterol. J. Biol.
Chem. 274, 6979–6991.
[95] Issandou, M. and Gramd-Perret, T. (2000) Multidrug resistance
P-glycoprotein is not involved in cholesterol esteriﬁcation.
Biochem. Biophys. Res. Commun. 279, 369–377.
[96] Le Goﬀ, W., Settle, M., Greene, D.J., Morton, R.E. and Smith,
J.D. (2006) Reevaluation of the role of the multidrug-resistant P-
glycoprotein in cellular cholesterol homeostasis. J. Lipid Res. 47,
51–58.
[97] Smit, J.J., Schinkel, A.H., Oude Elferink, R.P., Groen, A.K.,
Wagenaar, E., van Deemter, L., Mol, C.A., Ottenhoﬀ, R., van
der Lugt, N.M. and van Roon, M.A., et al. (1993) Homozygous
disruption of the murine mdr2 P-glycoprotein gene leads to a
complete absence of phospholipid from bile and to liver disease.
Cell 75, 451–462.
[98] Engel, T., Lorkowski, S., Lueken, A., Rust, S., Schluter, B.,
Berger, G., Cullen, P. and Assmann, G. (2001) The human
ABCG4 gene is regulated by oxysterols and retinoids in
monocyte-derived macrophages. Biochem. Biophys. Res. Com-
mun. 288, 483–488.
[99] Cserepes, J., Szentpetery, Z., Seres, L., Ozvegy-Laczka, C.,
Langmann, T., Schmitz, G., Glavinas, H., Klein, I., Homolya,
L., Varadi, A., Sarkadi, B. and Elkind, N.B. (2004) Functional
expression and characterization of the human ABCG1 and
ABCG4 proteins: indications for heterodimerization. Biochem.
Biophys. Res. Commun. 320, 860–867.
[100] Bretscher, M.S. (1972) Asymmetrical lipid bilayer structure for
biological membranes. Nat. New Biol. 236, 11–12.
[101] Daleke, D.L. (2003) Regulation of transbilayer plasma mem-
brane phospholipid asymmetry. J. Lipid Res. 44, 233–242.
[102] Holthuis, J.C. and Levine, T.P. (2005) Lipid traﬃc: ﬂoppy drives
and a superhighway. Nat. Rev. Mol. Cell Biol. 6, 209–220.
[103] Sims, P.J. and Wiedmer, T. (2001) Unraveling the mysteries of
phospholipid scrambling. Thromb. Haemost. 86, 266–275.
[104] Dekkers, D.W., Comfurius, P., van Gool, R.G., Bevers, E.M.
and Zwaal, R.F. (2000) Multidrug resistance protein 1 regulates
lipid asymmetry in erythrocyte membranes. Biochem. J. 350,
531–535.
[105] Dekkers, D.W., Comfurius, P., Schroit, A.J., Bevers, E.M. and
Zwaal, R.F. (1998) Transbilayer movement of NBD-labeled
phospholipids in red blood cell membranes: outward-directed
transport by the multidrug resistance protein 1 (MRP1).
Biochemistry 37, 14833–14837.
[106] Van Helvoort, A., Smith, A.J., Sprong, H., Fritzsche, I.,
Schinkel, A.H., Borst, P. and van Meer, G. (1996) MDR1 P-
glycoprotein is a lipid translocase of broad speciﬁcity, while
5596 M. Pennings et al. / FEBS Letters 580 (2006) 5588–5596MDR3 P-glycoprotein speciﬁcally translocates phosphatidylcho-
line. Cell 87, 507–517.
[107] Bosch, I., Dunussi-Joannopoulos, K., Wu, R.L., Furlong, S.T.
and Croop, J. (1997) Phosphatidylcholine and phosphatidyleth-
anolamine behave as substrates of the human MDR1 P-
glycoprotein. Biochemistry 36, 5685–5694.
[108] Eckford, P.D. and Sharom, F.J. (2005) The reconstituted P-
glycoprotein multidrug transporter is a ﬂippase for glucosylcer-
amide and other simple glycosphingolipids. Biochem. J. 389,
517–526.
[109] Smith, A.J., Timmermans-Hereijgers, J.L., Roelofsen, B., Wirtz,
K.W., van Blitterswijk, W.J., Smit, J.J., Schinkel, A.H. and
Borst, P. (1994) The human MDR3 P-glycoprotein promotes
translocation of phosphatidylcholine through the plasma mem-
brane of ﬁbroblasts from transgenic mice. FEBS Lett. 354, 263–
266.
[110] Kalin, N., Fernandes, J., Hrafnsdottir, S. and van Meer, G.
(2004) Natural phosphatidylcholine is actively translocated
across the plasma membrane to the surface of mammalian cells.
J. Biol. Chem. 279, 33228–33236.
[111] Hamon, Y., Broccardo, C., Chambenoit, O., Luciani, M.F.,
Toti, F., Chaslin, S., Freyssinet, J.M., Devaux, P.F., McNeish,
J., Marguet, D. and Chimini, G. (2000) ABC1 promotes
engulfment of apoptotic cells and transbilayer redistribution of
phosphatidylserine. Nat. Cell Biol. 2, 399–406.
[112] Chambenoit, O., Hamon, Y., Marguet, D., Rigneault, H.,
Rosseneu, M. and Chimini, G. (2001) Speciﬁc docking of
apolipoprotein A-I at the cell surface requires a functional
ABCA1 transporter. J. Biol. Chem. 276, 9955–9960.
[113] Smith, J.D., Waelde, C., Horwitz, A. and Zheng, P. (2002)
Evaluation of the role of phosphatidylserine translocase activity
in ABCA1-mediated lipid eﬄux. J. Biol. Chem. 277, 17797–
17803.
[114] Wang, N., Silver, D.L., Thiele, C. and Tall, A.R. (2001) ATP-
binding cassette transporter A1 (ABCA1) functions as a choles-
terol eﬄux regulatory protein. J. Biol. Chem. 276, 23742–23747.
[115] Kobayashi, A., Takanezawa, Y., Hirata, T., Shimizu, Y.,
Misasa, K., Kioka, N., Arai, H., Ueda, K. and Matsuo, M.
(2006) Eﬄux of sphingomyelin, cholesterol and phosphatidyl-
choline by ABCG1. J. Lipid Res. 15 (May), (Epub ahead of
print).
[116] Berge, K.E., Tian, H., Graf, G.A., Yu, L., Grishin, N.V.,
Schultz, J., Kwiterovich, P., Shan, B., Barnes, R. and Hobbs,
H.H. (2000) Accumulation of dietary cholesterol in sitosterol-
emia caused by mutations in adjacent ABC transporters. Science
290, 1771–1775.
[117] Weng, J., Mata, N.L., Azarian, S.M., Tzekov, R.T., Birch, D.G.
and Travis, G.H. (1999) Insights into the function of Rim
protein in photoreceptors and etiology of Stargardt’s disease
from the phenotype in abcr knockout mice. Cell 98, 13–23.[118] Pomorski, T., Holthuis, J.C., Herrmann, A. and van Meer, G.
(2004) Tracking down lipid ﬂippases and their biological
functions. J. Cell Sci. 117, 805–813.
[119] van Meer, G. and Sprong, H. (2004) Membrane lipids and
vesicular traﬃc. Curr. Opin. Cell Biol. 16, 373–378.
[120] Sprong, H., van der Sluijs, P. and van Meer, G. (2001) How
proteins move lipids and lipids move proteins. Nat. Rev. 2, 504–
513.
[121] Muller, P., Pomorski, T. and Herrmann, A. (1994) Incorpora-
tion of phospholipid analogues into the plasma membrane
aﬀects ATP-induced vesiculation of human erythrocyte ghosts.
Biochem. Biophys. Res. Commun. 199, 881–887.
[122] Farge, E. (1995) Increased vesicle endocytosis due to an increase
in the plasma membrane phosphatidylserine concentration.
Biophys. J. 69, 2501–2506.
[123] Farge, E., Ojcius, D.M., Subtil, A. and Dautry-Varsat, A. (1999)
Enhancement of endocytosis due to aminophospholipid trans-
port across the plasma membrane of living cells. Am. J. Physiol.
276, C725–C733.
[124] Pomorski, T., Lombardi, R., Riezman, H., Devaux, P.F., van
Meer, G. and Holthuis, J.C. (2003) Drs2p-related P-type
ATPases Dnf1p and Dnf2p are required for phospholipid
translocation across the yeast plasma membrane and serve a
role in endocytosis. Mol. Biol. Cell 14, 1240–1254.
[125] Zha, X., Genest Jr., J. and McPherson, R. (2001) Endocytosis is
enhanced in Tangier ﬁbroblasts: possible role of ATP-binding
cassette protein A1 in endosomal vesicular transport. J. Biol.
Chem. 276, 39476–39483.
[126] Alder-Baerens, N., Muller, P., Pohl, A., Korte, T., Hamon, Y.,
Chimini, G., Pomorski, T. and Herrmann, A. (2005) Headgroup-
speciﬁc exposure of phospholipids in ABCA1-expressing cells. J.
Biol. Chem. 280, 26321–26329.
[127] Buono, C., Waldo, S.W. and Kruth, H.S. (2006) LXRs inhibit
cholesterol accumulation and LDL uptake by macropinocytosis
in macrophages diﬀerentiated from human monocytes with M-
CSF in vitro. Arterioscler. Thromb. Vasc. Biol. 26, e-48.
[128] Pennings, M., Hildebrand, R.B., Van Berkel, Th.J.C., Groen,
A.K. and Van Eck, M. (2005) Macrophage ABCB4 deﬁciency
promotes atherosclerotic lesion development in LDL receptor
knockout mice. Circulation 112, SII-257.
[129] Pennings, M., Hildebrand, R.B., Van Berkel, Th.J.C., Groen,
A.K. and Van Eck, M. (2006) Macrophage ABCB4 deﬁciency
promotes atherosclerotic lesion development in LDL receptor
knockout mice. Atherosclerosis Suppl. 7, 319–320.
[130] Fonarow, G.C. and Watson, K.E. (2003) Eﬀective strategies for
long-term statin use. Am. J. Cardiol. 92, 27I–34I.
[131] Kastelein, J.J. (2003) The future of lipid-lowering therapy: the
big picture. Neth. J. Med. 61, 35–39.
[132] Graham, T.R. (2004) Flippases and vesicle-mediated protein
transport. Trends Cell Biol. 14, 670–677.
